Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23471131 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)
Condition: Kidney Disease
Interventions: Drug: Lanthanum Carbonate;   Other: 900 mg Phosphate Diet;   Drug: LC Placebo;   Other: Ad Libitum Diet

Indicates status has not been verified in more than two years